- Home
- / Advagene Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Advagene Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$23.9
2024-10-29
Market Capitalization
NT$1.4 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 15, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 13.6M | 4.9M | 3.9M | 168.0K | 56.0K | |||
| Operating expense total | 120.6M | 91.9M | 67.9M | 86.7M | 108.2M | 81.3M | 68.6M | 68.7M |
| Depreciation and amortization | 5.1M | 6.9M | 7.9M | 7.7M | 11.6M | 12.0M | 2.2M | 2.2M |
| EBITDA | (107.0M) | (87.0M) | (64.0M) | (86.5M) | (108.2M) | (81.3M) | (68.6M) | (68.7M) |
| EBIT | (111.5M) | (93.5M) | (71.8M) | (94.2M) | (119.8M) | (93.3M) | (70.8M) | (70.9M) |
| Interest income | 182.0K | 1.9M | 1.7M | 1.5M | 1.3M | 1.0M | 1.7M | 2.6M |
| Interest expense | 32.0K | 107.0K | 127.0K | 81.0K | 36.0K | 151.0K | 175.0K | |
| Pre tax profit | (111.3M) | (91.6M) | (70.2M) | (92.7M) | (118.4M) | (92.1M) | (69.4M) | (68.3M) |
| Net Income | (111.3M) | (91.6M) | (70.2M) | (92.7M) | (118.4M) | (92.1M) | (69.4M) | (68.3M) |